Format

Send to

Choose Destination
Infect Drug Resist. 2011;4:43-53. doi: 10.2147/IDR.S12714. Epub 2011 Feb 3.

Update on the optimal use of voriconazole for invasive fungal infections.

Author information

1
Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA;

Abstract

Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.

KEYWORDS:

aspergillosis; candidiasis; therapeutic drug monitoring; voriconazole

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center